#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Dermatitis atopic Dementia Alzheimer's type Asthma Breast cancer metastatic Type 2 diabetes mellitus Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Breast angiosarcoma Cervix carcinoma Inclusion body myositis Asthma Oesophageal achalasia Paraganglion neoplasm Pulmonary arterial hypertension Dedifferentiated liposarcoma Skin angiosarcoma Dent's disease Small for dates baby Acute lymphocytic leukaemia recurrent Cerebral amyloid angiopathy Porphyria non-acute Marginal zone lymphoma More trials…

    Learn about Rare Diseases

    Mucopolysaccharidosis Haemophilia B with anti factor IX – Treatment Idiopathic pulmonary fibrosis – Basic Information Combined immunodeficiency – Diagnostics Niemann-Pick disease – Treatment Nephroblastoma – Trials in Disease Nodal marginal zone B-cell lymphoma – Diagnostics Choroid melanoma – Basic Information Hereditary angioedema with C1 esterase inhibitor deficiency – Life with Disease Turner’s syndrome – Basic Information More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Hst-1011 Surzebiclimab Verapamil Hydrochloride Zipalertinib Basimglurant Bjt-778 Ezetimibe Indacaterol Acetate Belinostat Lurasidone Anselamimab ALENDRONATE SODIUM TRIHYDRATE Pamidronate Disodium Betula Verrucosa Pollen Bemarituzumab Evg321 Lacutamab Doxazosin Human Plasma Protein ORX750 More therapies…

    Learn about Your Condition

    Mental disorder Lymphocyte adoptive therapy Hepatitis alcoholic Paraesthesia Abdominal pain Coagulopathy Oxygen therapy Neuroblastoma VEXAS syndrome Tetanus Malignant melanoma stage IV Crigler-Najjar syndrome Rhabdomyosarcoma recurrent Antithrombin III deficiency Ovarian cancer recurrent More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Institut de Cancérologie Hématologie Universitaire…

Institut de Cancérologie Hématologie Universitaire de Saint Etienne (iCHUSE)

Avenue Albert Raimond, Saint Priest En Jarez, 42270, France

Want to learn more about this study or check if you can participate? Contact us.

  • Study of precemtabart tocentecan alone or in drug combination versus standard therapy in previously treated metastatic colorectal cancer patients

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Colorectal cancer metastatic
    Investigated Drugs:
    • Bevacizumab
    • Tipiracil Hydrochloride
    • Trifluridine
    Austria Belgium Denmark France Germany Italy +3

  • A study testing XmAb942 compared to placebo in adults with moderate-to-severe active ulcerative colitis

    Recruiting

    2 1
    Investigated Drugs:
    • XMAB942
    Bulgaria Croatia France Germany Greece Hungary +5

  • A Phase 3 Study of Sapablursen Compared with Placebo in Adults with Polycythemia Vera

    Recruiting

    3 1
    Investigated Diseases:
    • Polycythaemia vera
    Investigated Drugs:
    • Sapablursen
    Austria Czechia France Germany Hungary Italy +3

  • Study of mirikizumab and tirzepatide for adults with moderate to severe Crohn’s disease who are overweight or obese

    Recruiting

    3 1
    Investigated Drugs:
    • Tirzepatide
    • Mirikizumab
    Austria Belgium Bulgaria Czechia Denmark France +9

  • Study of JNJ-78934804 (guselkumab and golimumab) versus guselkumab in adults with moderately to severely active Crohn’s disease

    Recruiting

    3 1 1
    Investigated Drugs:
    • Golimumab
    • Guselkumab
    Austria Belgium Czechia France Germany Greece +9

  • Efficacy and Safety of JNJ-78934804 (guselkumab and golimumab) in Adults with Moderately to Severely Active Ulcerative Colitis

    Recruiting

    3 1 1
    Investigated Drugs:
    • Golimumab
    • Guselkumab
    Austria Belgium Bulgaria Czechia Denmark France +11

  • Cabozantinib Maintenance Therapy vs Best Supportive Care in Osteosarcoma Patients in Complete Remission or with Residual Disease after First‑Line Chemotherapy

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Cabozantinib
    Denmark Finland France Italy The Netherlands Poland +2

  • Efficacy and safety of lunsekimig in adults with inadequately controlled eosinophilic COPD: a randomized, double‑blind, placebo‑controlled trial

    Recruiting

    4 1
    Investigated Diseases:
    • Chronic obstructive pulmonary disease
    Investigated Drugs:
    • LUNSEKIMIG
    Belgium Denmark Estonia Finland France Germany +7

  • Phase 3 Study of Enpatoran in Patients with Active Cutaneous Lupus Erythematosus (with or without Systemic Disease)

    Recruiting

    3 1
    Belgium Bulgaria France Germany Greece Italy +4

  • Phase 2 Study of Nemolizumab for Skin Thickening in Adults with Systemic Sclerosis

    Recruiting

    2 1 1 1
    Investigated Drugs:
    • Nemolizumab
    Bulgaria Croatia France Greece Italy Poland +1
1 2 3 … 46
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!